Insights Into Acute Lymphoblastic Leukemia Midwest (ALL)

Perspectives on current treatment practices in the midwest region of the US regarding adult and AYA ALL, the role of MRD, and current treatment practices regarding relapsed disease

Midwest – September 17, 2020
Purchase Report

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

Insights on the following therapies were obtained

  • pegaspargase
  • asparaginase
  • imatinib
  • dasatinib
  • ponatinib
  • blinatumomab
  • inotuzumab ozogamicin
  • chimeric antigen receptor (CAR) T-cell therapy

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated roundtable discussion focusing on treatment of ALL in the midwest region of the US
  • Disease state and data presentations were developed in conjunction with a medical expert from MD Anderson Cancer Center
  • The group of advisors comprised community oncologists from the Midwest (USA)
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.